474 related articles for article (PubMed ID: 24028755)
1. Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome.
Gates S; Perkins GD; Lamb SE; Kelly C; Thickett DR; Young JD; McAuley DF; Snaith C; McCabe C; Hulme CT; Gao Smith F
Health Technol Assess; 2013 Sep; 17(38):v-vi, 1-87. PubMed ID: 24028755
[TBL] [Abstract][Full Text] [Related]
2. Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome.
Perkins GD; Gates S; Lamb SE; McCabe C; Young D; Gao F
Trials; 2011 May; 12():113. PubMed ID: 21554679
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial.
Gao Smith F; Perkins GD; Gates S; Young D; McAuley DF; Tunnicliffe W; Khan Z; Lamb SE;
Lancet; 2012 Jan; 379(9812):229-35. PubMed ID: 22166903
[TBL] [Abstract][Full Text] [Related]
4. The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up.
Walsh TS; Stanworth S; Boyd J; Hope D; Hemmatapour S; Burrows H; Campbell H; Pizzo E; Swart N; Morris S
Health Technol Assess; 2017 Oct; 21(62):1-118. PubMed ID: 29067906
[TBL] [Abstract][Full Text] [Related]
5. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial.
Perkins GD; McAuley DF; Thickett DR; Gao F
Am J Respir Crit Care Med; 2006 Feb; 173(3):281-7. PubMed ID: 16254268
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled trial and cost-effectiveness analysis of high-frequency oscillatory ventilation against conventional artificial ventilation for adults with acute respiratory distress syndrome. The OSCAR (OSCillation in ARDS) study.
Lall R; Hamilton P; Young D; Hulme C; Hall P; Shah S; MacKenzie I; Tunnicliffe W; Rowan K; Cuthbertson B; McCabe C; Lamb S;
Health Technol Assess; 2015 Mar; 19(23):1-177, vii. PubMed ID: 25800686
[TBL] [Abstract][Full Text] [Related]
7. Best evidence in critical care medicine: The role of neuromuscular blocking drugs in early severe acute respiratory distress syndrome.
Needham CJ; Brindley PG
Can J Anaesth; 2012 Jan; 59(1):105-8. PubMed ID: 22042702
[TBL] [Abstract][Full Text] [Related]
8. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.
McAuley DF; Cross LM; Hamid U; Gardner E; Elborn JS; Cullen KM; Dushianthan A; Grocott MP; Matthay MA; O'Kane CM
Lancet Respir Med; 2017 Jun; 5(6):484-491. PubMed ID: 28526233
[TBL] [Abstract][Full Text] [Related]
9. Immunonutrition for acute respiratory distress syndrome (ARDS) in adults.
Dushianthan A; Cusack R; Burgess VA; Grocott MP; Calder PC
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012041. PubMed ID: 30677127
[TBL] [Abstract][Full Text] [Related]
10. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Dixon B; Smith RJ; Campbell DJ; Moran JL; Doig GS; Rechnitzer T; MacIsaac CM; Simpson N; van Haren FMP; Ghosh AN; Gupta S; Broadfield EJC; Crozier TME; French C; Santamaria JD;
Lancet Respir Med; 2021 Apr; 9(4):360-372. PubMed ID: 33493448
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.
Villar J; Ferrando C; Martínez D; Ambrós A; Muñoz T; Soler JA; Aguilar G; Alba F; González-Higueras E; Conesa LA; Martín-Rodríguez C; Díaz-Domínguez FJ; Serna-Grande P; Rivas R; Ferreres J; Belda J; Capilla L; Tallet A; Añón JM; Fernández RL; González-Martín JM;
Lancet Respir Med; 2020 Mar; 8(3):267-276. PubMed ID: 32043986
[TBL] [Abstract][Full Text] [Related]
12. Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.
Ranieri VM; Pettilä V; Karvonen MK; Jalkanen J; Nightingale P; Brealey D; Mancebo J; Ferrer R; Mercat A; Patroniti N; Quintel M; Vincent JL; Okkonen M; Meziani F; Bellani G; MacCallum N; Creteur J; Kluge S; Artigas-Raventos A; Maksimow M; Piippo I; Elima K; Jalkanen S; Jalkanen M; Bellingan G;
JAMA; 2020 Feb; 323(8):725-733. PubMed ID: 32065831
[TBL] [Abstract][Full Text] [Related]
13. First do no harm: surrogate endpoints and the lesson of β-agonists in acute lung injury.
Lakshminarayana PH; Kahn JM
Crit Care; 2012 Jun; 16(3):314. PubMed ID: 22731873
[TBL] [Abstract][Full Text] [Related]
14. Pressure-controlled versus volume-controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).
Chacko B; Peter JV; Tharyan P; John G; Jeyaseelan L
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD008807. PubMed ID: 25586462
[TBL] [Abstract][Full Text] [Related]
15. Neuromuscular blockers in early acute respiratory distress syndrome.
Papazian L; Forel JM; Gacouin A; Penot-Ragon C; Perrin G; Loundou A; Jaber S; Arnal JM; Perez D; Seghboyan JM; Constantin JM; Courant P; Lefrant JY; Guérin C; Prat G; Morange S; Roch A;
N Engl J Med; 2010 Sep; 363(12):1107-16. PubMed ID: 20843245
[TBL] [Abstract][Full Text] [Related]
16. MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children.
Powell CV; Kolamunnage-Dona R; Lowe J; Boland A; Petrou S; Doull I; Hood K; Williamson PR;
Health Technol Assess; 2013 Oct; 17(45):v-vi, 1-216. PubMed ID: 24144222
[TBL] [Abstract][Full Text] [Related]
17. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial.
Fowler AA; Truwit JD; Hite RD; Morris PE; DeWilde C; Priday A; Fisher B; Thacker LR; Natarajan R; Brophy DF; Sculthorpe R; Nanchal R; Syed A; Sturgill J; Martin GS; Sevransky J; Kashiouris M; Hamman S; Egan KF; Hastings A; Spencer W; Tench S; Mehkri O; Bindas J; Duggal A; Graf J; Zellner S; Yanny L; McPolin C; Hollrith T; Kramer D; Ojielo C; Damm T; Cassity E; Wieliczko A; Halquist M
JAMA; 2019 Oct; 322(13):1261-1270. PubMed ID: 31573637
[TBL] [Abstract][Full Text] [Related]
18. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial.
Calfee CS; Delucchi KL; Sinha P; Matthay MA; Hackett J; Shankar-Hari M; McDowell C; Laffey JG; O'Kane CM; McAuley DF;
Lancet Respir Med; 2018 Sep; 6(9):691-698. PubMed ID: 30078618
[TBL] [Abstract][Full Text] [Related]
19. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma.
Travers AH; Milan SJ; Jones AP; Camargo CA; Rowe BH
Cochrane Database Syst Rev; 2012 Dec; 12():CD010179. PubMed ID: 23235685
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
